Nature Reviews Drug Discovery contents August 2012 Volume 11 Number 8 pp 581-652

Advertisement
Roche's X-tremeGENE Transfection Reagents Transfect efficiently with low cytotoxicity - proven in 275 different cell types...over 130 cancer cells. Free sample and protocols at http://www.x-tremegene.roche.com For life science research only. Not for use in diagnostic procedures.
TABLE OF CONTENTS
August 2012 Volume 11 Number 8
Impact Factor 29.008 *	In this issue Comment News and Analysis Research Highlights Reviews Also this month  Featured article: Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases Charles A. Dinarello, Anna Simon & Jos W. M. van der Meer
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
SciBX: Science - Business eXchange from NPG and BioCentury Joining the scientific acumen of NPG and the business intelligence of BioCentury to evaluate new developments in life science and technology that have commercial and investment potential for the pharmaceutical and biotechnology industries. Visit www.SciBX.com to reserve your copy of this new weekly groundbreaking publication today.
Advertisement
BioPartnering Latin America™ (BPL) Hotel Sofitel Copacabana in Rio de Janeiro, Brazil 11-13 September 2012 This event is focused on showcasing innovation, establishing strategic contacts, generating business through face-to-face meetings and promoting high-level networking. We hope you join us in Rio this September. www.techvision.com/bpl/?src=innavaroph
In this issue p581 | doi:10.1038/nrd3817 Full Text
Comment: DSM-5 and clinical trials in psychiatry: challenges to come? Florence Butlen-Ducuing, Manuel Haas, Luca Pani, Barbara van Zwieten-Boot & Karl Broich p583 | doi:10.1038/nrd3811 The publication of the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) in 2013 raises important questions for clinical trials and associated regulatory decisions on new drugs for psychiatric disorders. Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Overtaking the DILI Model-T Alisa Opar p585 | doi:10.1038/nrd3818 A new €32 million project aimed at understanding drug-induced liver injury is the latest of several collaborative efforts that could help drug firms better test for candidate-killing toxicity signals. PDF
PDUFA V goes back to basics Asher Mullard p586 | doi:10.1038/nrd3819 20 years after the first PDUFA provided the FDA with additional resources, regulators and industry are refocusing on review times and approval rates. PDF
NEWS IN BRIEF Network pharmacology moves into the clinic | Obesity drugs prevail | Antibacterial mAb heads back to the FDA p589 | doi:10.1038/nrd3821 PDF
BIOBUSINESS BRIEFS Deal watch: Roche deal targets glutamate in neurodevelopmental disorders Charlotte Harrison p590 | doi:10.1038/nrd3808 PDF
BIOBUSINESS BRIEFS Trial watch: Novel antimicrobial fights TB resistance Sarah Crunkhorn p590 | doi:10.1038/nrd3809 PDF
PATENT WATCH Road to unitary European patent hits a bump | Teva's Copaxone patents upheld | Presumed valid | Fatty acid receptor modulators Charlotte Harrison p592 | doi:10.1038/nrd3820 PDF
AN AUDIENCE WITH Jane Reese-Coulbourne p594 | doi:10.1038/nrd3812 Jane Reese-Coulbourne, executive director of the Reagan-Udall Foundation, discusses how long-awaited federal funding will be used to support the FDA's regulatory science. PDF
FROM THE ANALYST'S COUCH A new dawn in the sleep disorders pipeline? Waldemar Ockert p595 | doi:10.1038/nrd3789 This article investigates current unmet needs in the treatment of sleep disorders, and how understanding of their molecular biology has led to the development of exciting pipeline candidates. PDF
PIPELINE PIONEERS Pasireotide Richard A. Feelders, Uma Yasothan & Peter Kirkpatrick p597 | doi:10.1038/nrd3788 Somatostatin analogue approved as the first pharmacotherapy for Cushing's disease in the European Union. PDF
RESEARCH HIGHLIGHTS Top Autoimmune disease: Targeting IL-7 reverses type 1 diabetes p599 | doi:10.1038/nrd3805 PDF Metabolic disorders: New target for appetite control p600 | doi:10.1038/nrd3803 PDF Neurodegenerative disorders: Reversing Huntington's disease p600 | doi:10.1038/nrd3804 PDF Cancer: PD1 makes waves in anticancer immunotherapy p601 | doi:10.1038/nrd3806 PDF Anticancer drugs: Antitumour potential of catalytic DNA p602 | doi:10.1038/nrd3807 PDF IN BRIEF Adverse drug reactions: Computational model predicts side effects | Psychiatric disorders: Targeting a PI3K subunit in schizophrenia | Obesity and diabetes: Adenosine pathway increases ß-cell regeneration | Anticancer drugs: Synthetic lethality enables targeting of MYC PDF Drug Discovery JOBS of the week Principal Investigator positions in Biological Chemistry & Drug Discovery University of Dundee, College of Life Sciences Postdoctoral Position in Drug Discovery Research Shanghai Jiao Tong University Shanghai Center for Systems Biomedicine Postdoctoral Fellow Sanford-Burnham Medical Research Institute Institute Research Scientist – Drug Metabolism MD Anderson Cancer Center PhD studentship on large-scale quantum chemistry methods applied to drug discovery University of Southampton - Chemistry More Science jobs from Drug Discovery EVENT "Autophagy as a Therapeutic Target in Multiple Diseases: From Molecular Mechanisms to Drug Discovery 25.09.12 NY, US More science events from
Advertisement
Knome provides researchers and clinics with human whole genome interpretation software and services. Visit www.knome.com to learn how we can help you identify the variants, genes, and gene sets that underlie disease and drug response.
REVIEWS		Top
G protein-coupled receptors for energy metabolites as new therapeutic targets Clara C. Blad, Cong Tang & Stefan Offermanns p603 | doi:10.1038/nrd3777 A growing number of G protein-coupled receptors (GPCRs) are being identified as sensors for ligands that are energy substrates or metabolic intermediates, and their central role in the coordination of metabolic processes is increasingly being recognized. Offermanns and colleagues summarize the function of these metabolite-sensing GPCRs in physiology and disease, and discuss the emerging pharmacological agents that are being developed to target these GPCRs for the treatment of metabolic disorders. Abstract | Full Text | PDF
Revisiting lab-on-a-chip technology for drug discovery Pavel Neužil, Stefan Giselbrecht, Kerstin Länge, Tony Jun Huang & Andreas Manz p620 | doi:10.1038/nrd3799 Manz and colleagues discuss recent progress in the development of microfluidic techniques (lab-on-a-chip technology) and their applications in drug discovery. Highlights include high-throughput droplet technology and applications such as 'organs on a chip', which could help reduce reliance on animal testing. Abstract | Full Text | PDF
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases Charles A. Dinarello, Anna Simon & Jos W. M. van der Meer p633 | doi:10.1038/nrd3800 Blockade of the pro-inflammatory cytokine interleukin-1 (IL-1) is emerging as an effective approach for the treatment of an increasing number of diseases. Here, Dinarello and colleagues discuss the pathogenic roles of IL-1, present therapeutic strategies aimed at modulating the activity of this cytokine and review clinical trial data for multiple indications. Abstract | Full Text | PDF | Supplementary information
Advertisement
Nature Outlook: Taste Taste is central to our being, but this vital sense is only now becoming clear at the biological level. Nature Outlook: Taste reports the latest findings from the front lines of flavour. Access the Outlook free online for six months. Produced with support from: Ajinomoto Co., Inc.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2010 Journal Citation Report (Thomson Reuters, 2011)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.